Market Challenges And Opportunities
Global Dupuytren’s Disease Market Drivers:
- Increasing prevalence of Dupuytren’s disease: The prevalence of Dupuytren’s disease is expected to drive the growth of the market over the forecast period. For instance, according to data published in October 2020 by the National Library of Medicine, the prevalence of Dupuytren’s disease in the world is found to be 8.2% (95% CI 5.7–11.7%). The highest prevalence rate is reported in Africa with 17.2% (95% CI 13–22.3%) in 2020.
- Increasing research and development activities: Increasing research and development activities by the key players in the market are expected to drive the growth of the market over the forecast period. For instance, in June 2022, a research team at the Kennedy Institute, University of Oxford, based in U.K., led by Professor Jagdeep Nanchahal have proven that the anti-TNF drug adalimumab is effective in treating patients with early stage Dupuytren’s disease.
- Increasing awareness of Dupuytren's disease: One of the key drivers contributing towards the growth of Dupuytren's disease market is the increasing awareness about the condition. Dupuytren's disease is a hereditary disease that causes thickening and contraction of the palmar fascia in the hand resulting in fingers curling inward towards the palm. However, for a long time this condition remained under-diagnosed majorly due to lack of awareness among both patients and physicians. Now, with increasing efforts by medical practitioners, patient advocacy groups and pharmaceutical companies, awareness levels have risen significantly. Various awareness campaigns and educational initiatives are bringing Dupuytren's disease into the spotlight and enabling correct diagnosis. For example, support groups are educating how this condition is different from other musculoskeletal problems and emphasize on early intervention. Also, the recent recognition of Dupuytren's disease as a real medical condition by leading medical bodies has endorsed it as an area that requires more clinical research and treatment innovation. This recognition has prompted more discussions around the disease in peer reviewed journals, patient conferences, and social media. As a result of the growing awareness, patients who may have early symptoms are now able to recognize it and seek medical help in a timely manner rather.
- Growing geriatric population: As the world population is aging rapidly, more and more people are falling prey to Dupuytren's disease. Old age is one of the major risk factors for this condition as the incidence and prevalence of Dupuytren's disease increases with increasing age. According to some estimations, Dupuytren's disease affects nearly 10% of the population aged over 60 years and 20% of the population aged over 80 years. With increased life expectancy and declining birth rates, countries around the world are witnessing a consistent rise in the percentage of the geriatric population in their total population. This demographic shift is expected to significantly fuel the need for effective treatment procedures of age-related conditions such as Dupuytren's disease in the coming years. With a growing pool of aging individuals worldwide, the global Dupuytren's disease market is poised to experience substantial growth over the next decade
Global Dupuytren’s Disease Market Opportunities:
- Emerging economies: Emerging economies in regions like Asia Pacific, Latin America, Africa, and Eastern Europe present a huge opportunity for growth in the global Dupuytren's disease market. These regions are expected to see higher epidemiological occurrences of Dupuytren's disease in the coming years due to transformations in lifestyles, dietary habits and rising levels of obesity. Countries like India, China, Brazil, Mexico, Indonesia, and Nigeria have a very large patient pool suffering from undiagnosed or undermanaged Dupuytren's disease. As economic conditions and access to healthcare facilities improve in these nations, there will likely be a greater focus on diagnosing and treating previously neglected conditions like Dupuytren's disease.
- Expanding medical technologies: Expanding medical technologies offer a great opportunity for growth in the global Dupuytren’s disease market. Dupuytren’s disease is a progressive condition characterized by the growth of fibrous cords under the skin of the palm, which can slowly deform the fingers and reduce the hand's function. As of now, the only definitive treatment is surgical fasciectomy which removes these fibrous cords. However, the surgery often requires extensive wound healing and hand therapy, with potential risks of complications and relapse. Recent advancements in medical technologies present minimally invasive procedures that overcome many of the challenges associated with open fasciectomy. For example, needle aponeurotomy uses needles to break up problematic cords within the palm and fingers. This offers relief from hand deformity while avoiding significant wounds and scarring. Similarly, collagenase injections have emerged as a non-surgical option for early-stage Dupuytren's disease. Collagenase works by enzymatically dissolving the collagen cords, reducing contractures in a brief office procedure. According to statistics from Public Health England, collagenase treatment volumes have increased over 300% from 2018 to 2021 in the UK National Health System, reflecting its growing acceptance as an efficacious front-line therapy
- Increasing initiatives by the key players in the market: Increasing initiatives by the key players in the market are expected to drive the growth of the market over the forecast period. For instance, on May 17, 2023, Ventoux Biosciences, a pharmaceutical company, announced the launch of its efforts to deliver life-changing therapies for patients with Dupuytren's disease, a common, progressive, and debilitating fibrotic contracture that limits hand mobility. Ventoux Biosciences aims is to identify and develop novel treatments that will help patients across the full spectrum of the disease by delaying or reversing further progression.
- Increasing research and development activities: Increasing research and development activities by the key players are expected to drive the growth of the market over the forecast period. For instance, on June 26, 2023, Endo International plc, a global pharmaceutical company, announced that the first patient has been enrolled in Generating Real-world Ambispective data to Study Participant Treatment outcomes for Dupuytren's Contracture (GRASP-DC), a non-interventional registry of up to 1,000 patients with Dupuytren's contracture (DC). This registry will create the largest and most comprehensive collection of real-world DC data on treatment outcomes.
Global Dupuytren’s Disease Market Restraints:
- High cost of treatment: This high cost puts the surgery out of reach for many patients without proper health insurance. Patients sometimes find themselves unable to pay high co-pay requirements, even for those who have insurance. For instance, according to data published in July 2022 by Dotdash Media, Inc., a digital media company, average Dupuytren’s disease costs in the U.S. range between US$ 15,000 and US$ 30,000.
- Risks and complications associated with surgery: Surgery has traditionally been the primary treatment option for Dupuytren's disease. However, surgical procedures come with risks of complications that give patients pause. All surgeries carry risks of infection, nerve damage, joint stiffness, and recurrence of the disease. For Dupuytren's disease, which commonly affects the elderly population, these risks weigh heavy on patients and surgeons who must consider factors like healing time and recovery. The invasive nature of surgery itself poses drawbacks like postoperative pain, discomfort, and tenderness that can extend recovery periods substantially. For many elderly patients suffering from multiple conditions already, major surgery may not seem worth the added stress, pain, and risks to their health.
U.S.: 
U.K. : 
India : 
